This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary EP2 Therapeutic Antibody Development
The development of veterinary therapeutic antibodies targeting specific markers is emerging as a promising treatment strategy. EP2, a receptor for PGE2, can affect cancer cells in diseased animals and inhibit tumor immunity through various mechanisms. BioVenic offers comprehensive veterinary EP2 therapeutic antibody development services. Utilizing multiple technologies for the preparation of veterinary therapeutic antibodies, and continuously advancing antibody engineering, we strive to provide high-quality, highly effective antibodies.
Background of EP2
| Full Name | Prostaglandin E receptor 2 |
|---|---|
| Aliases | PTGER2. |
| Target Profile | EP2 is a member of the G protein-coupled receptor family, primarily mediating the physiological effects of Prostaglandin E2 (PGE2) and requiring high concentrations of PGE2 for effective signal generation. In the animal body, EP2 plays a crucial role in regulating inflammatory responses, pain perception, immune modulation, as well as cell proliferation and differentiation. Its abnormal activation is closely associated with the occurrence and development of tumor diseases. |
MoA of EP2
In normal bodies, EP2 interacts with prostaglandin E2, activating intracellular signaling pathways such as the cAMP/PKA/CREB pathway, which are crucial for mediating the anti-inflammatory and immune-suppressive aspects of PGE2. It plays a role in modulating cellular inflammatory responses by reducing the release of inflammatory mediators and the activation of immune cells. Additionally, the EP2 receptor mediates a G protein-independent pathway by binding to β-arrestin, leading to the activation of the JNK/Pfn-1/F-actin pathway, thereby promoting cell migration and proliferation. Tumor cells frequently exhibit abnormal responses to EP2 signaling, which may lead to uncontrolled cell proliferation and enhanced anti-apoptotic signals. EP2 may also be involved in immune evasion, where tumor cells change their surrounding environment to avoid attack by the immune system.
Fig.1 Schematic diagram of the activation of EP2 leads to both G protein-dependent and independent pathways.1
Application in Veterinary Therapeutics
EP2 has shown potential as a therapeutic target in the treatment of cancer in companion animals like felines and canines. EP2 is overexpressed in both feline and canine mammary tumor tissues, supporting the use of EP2 therapeutic antibodies to inhibit its expression. This approach can help mitigate the pathological processes mediated by the EP2 receptor. By blocking these signaling pathways, tumor growth and spread can be slowed, and it may also help in modulating the tumor microenvironment, thereby enhancing the immune system's response to the tumor.
Veterinary EP2 Therapeutic Antibody Development Services
The role of EP2 is often associated with the development and progression of cancer in animals. BioVenic offers comprehensive veterinary EP2 therapeutic antibody development services, including but not limited to the application of hybridoma technology, single B-cell technology, and phage display techniques. Our services also encompass antibody engineering, such as affinity maturation and the development of species-specific antibodies, aimed at enhancing therapeutic efficacy and safety.
For more information about our veterinary EP2 therapeutic antibody development services, please click the link below.
Why Choose Us?
BioVenic has established the veterinary therapeutic antibody development platform, including a variety of immunogens, immunization animals, antibody preparation techniques, and validation methods supplying for you to choose from.
We provide comprehensive antibody engineering services, taking into account the immunogenicity, affinity, and half-life of antibodies to enhance their potential therapeutic effects.
During the development process of veterinary therapeutic antibodies, we enforce strict quality control to aid in developing high-purity, high-concentration, and low-endotoxin antibodies.
EP2-mediated signaling is closely associated with the onset and progression of animal tumors and is an important target in inflammatory and cancer pain treatment. BioVenic offers veterinary EP2 therapeutic antibody development services, providing comprehensive support throughout the entire process, and helping you explore the therapeutic role of targeting EP2 in cancers and other diseases in companion animals like dogs, cats, and horses. If you have a project service need in this area, please contact us now!
References
- Sluter, Madison N., et al. "EP2 antagonists (2011–2021): a decade's journey from discovery to therapeutics." Journal of medicinal chemistry 64.16 (2021): 11816-11836.
- Millanta, Francesca, et al. "COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours." Veterinary and Comparative Oncology 14.3 (2016): 270-280.